Five Prime granted ADC exclusive development and commercialization rights to multiple human monoclonal antibodies against an undisclosed target

Five Prime Therapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$175.0m on 11/01/2013 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

ADC Therapeutics S.A.

Switzerland / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced